shares gained 7.9% after the company said its first-quarter loss widened, due in part to costs related to the Phase III lorcaserin Bloom trial. The first quarter of 2006 also included a $5 million milestone payment under its collaboration with Ortho-McNeil Pharmaceutical Inc. The San Diego biotechnology company had a first-quarter loss of $31.4 million, or 53 cents a share, compared with a loss of $12.7 million, or 30 cents a share, a year earlier. Arena said revenue for the quarter fell 60% to $4.91 million from $12.1 million a year earlier. This company is going to shoot up big. Look at all the pro's that even agree with me. I see this company going to at least $20-25.
$12.95 (04/23/07)
